/CERC

CERC Stock - Cerecor Inc.

Q: What is the analyst price target for CERC?

Analyst price target information is not currently available for CERC.

Q: What is CERC's market cap?

Market capitalization information is not currently available for CERC.

Healthcare|Biotechnology|NASDAQ

$2.93-1.68%

$0.05 (-1.68%) • Aug 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.22

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CERC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.44

52W High$4.50

52W Low$1.98

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024
Revenue	$441,000
Gross Profit	$-26,834,000
Gross Margin	-6084.8%
Operating Income	$-68,512,000
Net Income	$-35,129,000
Net Margin	-7965.8%
EPS	$-7.94

Company Overview

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Visit Website

Earnings History & Surprises

CERC

Beat Rate

33%

Last 12 quarters

Avg Surprise

-47.0%

EPS vs Estimate

Beats / Misses

4/8

Last 12 quarters

Latest EPS

$-0.18

Q3 2021

EPS Surprise History

Q2 19

+18.8%

$-0.13vs$-0.16

Q3 19

+21.4%

$-0.11vs$-0.14

Q4 19

+46.2%

$-0.07vs$-0.13

Q2 20

-240.0%

$-0.34vs$-0.10

Q3 20

-90.0%

$-0.19vs$-0.10

Q4 20

-88.9%

$-0.17vs$-0.09

Q2 21

-68.4%

$-0.32vs$-0.19

Q3 21

-5.9%

$-0.18vs$-0.17

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2021	Aug 2, 2021	$-0.17	$-0.18	-5.9%	✗ MISS
Q2 2021	May 13, 2021	$-0.19	$-0.32	-68.4%	✗ MISS
Q4 2020	Nov 9, 2020	$-0.09	$-0.17	-88.9%	✗ MISS
Q3 2020	Aug 6, 2020	$-0.10	$-0.19	-90.0%	✗ MISS
Q2 2020	May 7, 2020	$-0.10	$-0.34	-240.0%	✗ MISS
Q4 2019	Nov 14, 2019	$-0.13	$-0.07	+46.2%	✓ BEAT
Q3 2019	Aug 8, 2019	$-0.14	$-0.11	+21.4%	✓ BEAT
Q2 2019	May 9, 2019	$-0.16	$-0.13	+18.8%	✓ BEAT
Q4 2018	Nov 13, 2018	—	—	—	—
Q3 2018	Aug 9, 2018	—	—	—	—
Q2 2018	Apr 2, 2018	—	—	—	—
Q4 2017	Nov 6, 2017	—	—	—	—
Q3 2017	Aug 14, 2017	—	—	—	—
Q2 2017	May 9, 2017	$-0.37	$-0.19	+48.6%	✓ BEAT
Q4 2016	Nov 8, 2016	$-0.51	$-0.70	-37.3%	✗ MISS
Q2 2016	May 16, 2016	$-0.33	$-0.59	-78.8%	✗ MISS
Q1 2016	Mar 23, 2016	$-0.28	$-0.53	-89.3%	✗ MISS
Q4 2015	Oct 15, 2015	—	—	—	—